FDA gains power to police compounding pharmacies copying commercial drugs

What it does

This bill tightens federal oversight of compounding pharmacies and outsourcing facilities by restricting them from repeatedly copying commercially available drugs, requiring them to report when they compound copies of commercial drugs for out-of-state patients, and mandating more frequent inspections of large-scale outsourcing facilities. The bill aims to prevent compounding pharmacies from functioning as unlicensed drug manufacturers while preserving their legitimate role in customizing medications for individual patients.

Why we flagged it

The bill's operative mechanism is regulatory tightening: it restricts compounding pharmacies from copying commercial drugs at scale, requires reporting of out-of-state compounding, and mandates biennial inspections of large-scale facilities. These are safety and oversight measures, not market protection.

What the text implies

• The 20-times-per-month threshold for 'essentially a copy' compounding may be difficult for regulators to enforce without detailed pharmacy records; compliance burden falls on smaller compounders who lack IT infrastructure.
• The definition of 'essentially a copy' depends on prescriber judgment of 'significant difference' — this creates ambiguity and potential for regulatory disputes over subjective clinical determinations.
• Large-scale outsourcing facilities (>100 compounds/year) face biennial inspection mandates, but the bill does not specify inspection resource allocation; FDA may lack capacity to meet this timeline.
• Hospital pharmacy exclusion from reporting requirements may create a loophole: hospitals could compound copies of commercial drugs for out-of-state patients without triggering the reporting rule.
• The bill grants the Secretary discretion to set 'base establishment fees' to fund compounding oversight, but does not cap or specify the fee amount — potential for cost-shifting to compounders without legislative review.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain stronger safety oversight of compounding pharmacies, which have been linked to contamination and quality failures. The restrictions target pharmacy practices that circumvent FDA oversight by copying commercial drugs at scale, not legitimate patient-specific compounding. Patients receive medications from facilities subject to more rigorous inspection and reporting.

Who stands to gain

• Pharmaceutical manufacturers (reduced competition from compounded copies)
• FDA and HHS (increased inspection and enforcement budget authority)

Named in the bill

FDA, HHS Secretary, Compounding pharmacies, Outsourcing facilities, Hospital pharmacies, Pharmaceutical manufacturers

Where it stands

20 cosponsors: 15 Republicans, 5 Democrats.

• Dec 9, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 9, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

8 lobbying clients named this bill on 10 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $740,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 88% of bills with at least one filing.

Rudy Yakym, the sponsor, reported $1,401,759 in PAC receipts in the 2026 cycle. $10,000 of that came from 1 PAC tied to these lobbying clients.

• Professional Compounding Centers of America — $220,000 on 1 filing
• Tiber Creek Health Strategies, Inc. (on Behalf of Eli Lilly and Company) — $160,000 on 2 filings
• Eli Lilly and Company Fka Lilly Usa, LLC — $100,000 on 2 filings
• Alliance for Safe Online Pharmacies (asop Global) — $60,000 on 1 filing
• Novo Nordisk Inc. — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.